Business Description
Chewy, Inc., along with its affiliated entities, functions exclusively as an online retail enterprise within the United States. Through its primary website, chewy.com, and its mobile applications, the company provides a comprehensive range of products and services tailored for nearly every type of domestic companion, including canines, felines, aquatic pets, birds, small mammals, horses, and even reptiles. Customers can procure everything from essential pet food and treats to necessary supplies, prescribed medications, and other health and wellness items. This extensive inventory includes roughly 100,000 unique products supplied by approximately 3,000 different partner brands. Chewy was established in 2010 and maintains its corporate headquarters in Dania Beach, Florida.
Business History
Generated: Jun 13, 2026 3:03amPrice Overview
Last updated: Jun 13, 2026 3:00am (14d ago)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 0.53
Total Equity: $497.90M
Shares: 425,800,000
Total Debt: $38.10M
Cash: $860.10M
EBITDA: $397.20M
Total Debt: $38.10M
Cash: $860.10M
Revenue: $12.60B
Revenue: $12.60B
Revenue: $12.60B
Total Equity: $497.90M
Tax Rate: 15.4%
Equity: $497.90M
Total Debt: $38.10M
Cash: $860.10M
Current Liabilities: $2.30B
Long-Term Debt: $0.00
Total Debt: $38.10M
Total Equity: $497.90M
Shares: 425,800,000
Shares: 425,800,000
CapEx: -$129.20M
Shares: 425,800,000
Stock Price: $19.31
Net Income: $222.80M
Industry Benchmarks
Advanced Analysis Forensic deep-dive · three lenses
The business has visibly inflected. Revenue compounded from $8.97B (2022) to $12.60B (2026), with gross margin expanding 320bps from 26.6% to 29.8% and FCF scaling from $8.6M to $562.4M — a roughly 65x increase that materially outpaces revenue growth, evidencing real operating leverage. OCF/NI of 4.27x, accruals of -11.7% of assets, Beneish M of -2.68 and Altman Z of 4.67 paint a picture of clean, conservative earnings; if anything, GAAP NI ($222.8M) understates cash economics ($562.4M FCF).
Capital discipline is a genuine positive: diluted share CAGR of just 0.5% with buybacks running 154% of SBC means per-share value is being protected, a rarity in growth-era e-commerce. Net cash of $840.7M plus $562M/yr FCF removes survival risk entirely. The concern is that operating margin is still only 2.0% — the business is durable and cash-generative because of working-capital dynamics and scale, not because the underlying retail economics are fat. The heavy insider selling ($1.76B over 12 months, 23 sells / 0 buys) is notable but in context of the BC Partners/private-equity overhang it likely reflects sponsor monetization rather than a fundamental tell — needs verification.
Verify before trusting this (6)
- Whether the $1.76B of insider sales is BC Partners/sponsor secondary distribution vs. management discretionary selling — check Form 4 filer identity and 144 filings
- Source of the 2025 $392.7M NI spike — confirm deferred tax asset valuation allowance release in the 10-K
- Active customer count and net sales per active customer trend — is the top-line growth from customer adds or pricing/Autoship penetration
- Working capital contribution to FCF — how much of the $562M is structural (negative WC from Autoship) vs. true operating earnings
- Mix shift to Chewy Health/pharmacy and private-label as the GM expansion driver
- Capex plans for additional automated fulfillment centers — could compress FCF if step-function investment resumes
The e2e composite and signal-adjusted fair values both land at $17.70, against a current price of $19.31. That's roughly a 9% premium to deserved value — small, but the wrong direction for a margin of safety. The earnings-quality lens is favorable (clean accruals, $562M FCF on $12.6B revenue, flat share count, net cash) which supports the deserved value but doesn't justify paying above it. The Strong quality grade pulls deserved value up, but $17.70 already reflects that — I shouldn't double-count.
What's priced in at $19.31 on ~$8.0B market cap: continued Autoship-led revenue growth, gradual operating margin expansion off today's ~2%, and durable FCF conversion. That's a reasonable base case, not heroic — but it's also not discounted. For a thin-margin specialty retailer facing Amazon/Walmart/Instacart, the right entry is at or below intrinsic, not above it. There's no decisive mispricing here in either direction; this is the textbook 'good business the market understands' setup.
Verify before trusting this (5)
- Autoship as % of net sales and YoY growth — the core driver of FCF durability
- Operating margin trajectory and any guidance on structural margin ceiling
- Active customer count trend and net sales per active customer — gauges pricing power vs. saturation
- Capex and working capital trends to confirm FCF run-rate isn't flattered by one-offs
- Pace of insider selling in latest Form 4s
Sentiment pressure on CHWY is net positive but not euphoric. The narrative is a moderate-intensity, moderate-durability 'steady compounder / Amazon of pet' story with low cult coefficient - it isn't generating mania, but it isn't cracking either, and pet spend is treated by the market as a defensive-ish consumer category. Analyst tone is overwhelmingly constructive: 31 Buys vs 7 Holds, zero Sells, with 14 fresh upward revisions this month averaging a $32.93 target against a $17.95 price - that is a loud, recent, one-directional signal that the sell-side is leaning in, not trimming.
Verify before trusting this (4)
- Whether Autoship growth and active customer counts in the next print validate or break the compounder narrative
- Any Amazon or Walmart pet-category push that would reignite the bear story
- Direction of 10y yields and VIX - a move above 20 VIX would amplify the beta headwind
- Whether sell-side target revisions keep trending up or start to roll over
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 13, 2026 3:06am (14d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $9.0B | $10.1B | $11.1B | $11.9B | $12.6B |
| Cost of Revenue | $6.6B | $7.3B | $8.0B | $8.4B | $8.8B |
| Gross Profit | $2.4B | $2.8B | $3.2B | $3.5B | $3.8B |
| Operating Expenses | $2.5B | $2.8B | $3.2B | $3.4B | $3.5B |
| Operating Income | -$73.6M | $56.4M | -$23.6M | $112.6M | $254.3M |
| Net Income | -$75.2M | $49.9M | $39.6M | $392.7M | $222.8M |
| EBITDA | -$17.7M | $138.6M | $161.5M | $271.8M | $397.2M |
| EPS | $-0.18 | $0.12 | $0.09 | $0.93 | $0.53 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 13, 2026 3:03am (14d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $603.1M | $331.6M | $602.2M | $595.8M | $860.1M |
| Total Current Assets | $1.3B | $1.5B | $2.1B | $1.7B | $2.0B |
| Total Assets | $2.1B | $2.5B | $3.2B | $3.0B | $3.6B |
| Current Liabilities | $1.6B | $1.8B | $2.1B | $2.2B | $2.3B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.1B | $2.4B | $2.7B | $2.8B | $3.1B |
| Total Equity | $14.7M | $160.3M | $510.2M | $261.5M | $497.9M |
| Retained Earnings | -$2.0B | -$2.0B | -$2.0B | -$1.6B | -$1.4B |
Cash Flow (Annual)
Last updated: Jun 13, 2026 3:06am (14d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $191.7M | $349.6M | $486.2M | $596.3M | $691.6M |
| Capital Expenditure | -$183.2M | -$230.3M | -$143.3M | -$143.8M | -$129.2M |
| Free Cash Flow | $8.6M | $119.3M | $342.9M | $452.5M | $562.4M |
| Acquisitions (net) | $0 | -$40.0M | $-367,000 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | -$2.5M | $-5,000 | -$942.8M | -$262.5M |
| Net Change in Cash | $39.7M | -$272.6M | $270.6M | -$6.5M | $264.3M |
Analyst Estimates (Annual)
Last updated: Jun 13, 2026 3:00am (14d ago)| Metric | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|
| Revenue |
$14.5B $14.0B – $14.9B
|
$15.4B $15.4B – $15.5B
|
$16.4B $16.2B – $16.8B
|
$17.6B $17.3B – $18.0B
|
| EBITDA |
$986.7M $958.5M – $1.0B
|
$1.1B $1.1B – $1.1B
|
$1.1B $1.1B – $1.1B
|
$1.2B $1.2B – $1.2B
|
| Net Income |
$443.3M $415.0M – $531.2M
|
$543.4M $433.5M – $660.3M
|
$638.7M $625.8M – $657.2M
|
$728.1M $713.5M – $749.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 13, 2026 3:06am (14d ago)| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue Growth | +12.8% | +10.2% | +6.4% | +6.2% |
| Gross Profit Growth | +18.8% | +11.5% | +9.7% | +8.3% |
| Operating Income Growth | +176.7% | -141.9% | +576.6% | +125.9% |
| Net Income Growth | +166.3% | -20.7% | +892.3% | -43.3% |
| EBITDA Growth | +881.8% | +16.6% | +68.3% | +46.2% |
Insider Trading (Recent)
Last updated: Jun 13, 2026 3:06am (14d ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-01 | Singh Sumit | F-InKind | 7,567.00 | $22.54 | $170,560 |
| 2026-06-01 | Singh Sumit | F-InKind | 1,273.00 | $22.54 | $28,693 |
| 2026-06-01 | Billings William G. | F-InKind | 625.00 | $22.54 | $14,088 |
| 2026-06-01 | Deppe Christopher S. | F-InKind | 182.00 | $22.54 | $4,102 |
| 2026-06-01 | Hu Da-Wai | F-InKind | 445.00 | $22.54 | $10,030 |
| 2026-05-01 | Billings William G. | F-InKind | 1,064.00 | $25.42 | $27,047 |
| 2026-05-01 | Hu Da-Wai | F-InKind | 909.00 | $25.42 | $23,107 |
| 2026-05-01 | Deppe Christopher S. | F-InKind | 2,857.00 | $25.42 | $72,625 |
| 2026-05-01 | Singh Sumit | F-InKind | 15,462.00 | $25.42 | $393,044 |
| 2026-05-04 | Singh Sumit | S-Sale | 83,306.00 | $25.60 | $2.1M |
| 2026-05-01 | Singh Sumit | F-InKind | 2,172.00 | $25.42 | $55,212 |
| 2026-05-04 | Singh Sumit | S-Sale | 4,220.00 | $25.60 | $108,032 |
| 2026-04-08 | Billings William G. | A-Award | 32,571.00 | $0.00 | $0 |
| 2026-04-08 | Hu Da-Wai | A-Award | 37,486.00 | $0.00 | $0 |
| 2026-04-08 | Deppe Christopher S. | A-Award | 346,670.00 | $0.00 | $0 |
| 2026-04-08 | Deppe Christopher S. | A-Award | 71,062.00 | $0.00 | $0 |
| 2026-04-08 | Deppe Christopher S. | A-Award | 5,922.00 | $0.00 | $0 |
| 2026-04-08 | Singh Sumit | A-Award | 394,868.00 | $0.00 | $0 |
| 2026-04-08 | Singh Sumit | A-Award | 92,381.00 | $0.00 | $0 |
| 2026-04-08 | Singh Sumit | A-Award | 59,219.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).
Delvantic AI Findings
Looking at the raw quarterly trajectory first: revenue went $2.86B → $2.88B → $3.25B → $3.12B → $3.10B → $3.12B → $3.26B → $3.26B. The two most recent quarters are flagged as identical $3.26B/$39.2M which looks like a data duplication artifact, not a real print — caveat my read accordingly. Stripping that, YoY for the May 2025 quarter is roughly $3.12B vs $2.86B = ~9%, which is *better* than the 6.3% revenue CAGR suggests, not worse. But net income tells the real story: it collapsed from $299M in Jul-2024 (clearly a tax-benefit/one-timer — note that single quarter is bigger than any full year of NI in the dataset) to $3.9M, then rebuilt to $62M, and now decelerated back to $39M. Margins are stuck at 1-2%. The $562M FCF on $12.6B revenue is the real earnings power — ~4.5% FCF margin — and at $8B market cap that's ~14x FCF, which is not demanding for a category leader growing ~6-9%.
The synthesis verdict of "High Conviction Required" and the Market Forces "Neutral" read feel directionally right but lean too bearish on the Amazon threat. Chewy's Autoship + pharmacy/vet-services moat is genuinely differentiated in a way that the bear case underweights: Amazon has competed in pet for a decade and Chewy still grew 6%+ and expanded gross margin from 26.6% (FY22) to 29.8% (FY26). That's 320bps of gross margin expansion *during* the supposed Amazon onslaught — the opposite of what the bear story predicts. The Pre-Flight note calling this "high-growth" is wrong; this is clearly transitioning to mature compounder, and the rule-based "mature_earner" tag is more honest. The 40x PE is a red herring because NI is artificially depressed by working-capital and stock-comp dynamics; EV/FCF of ~13-14x is the metric that matters and it's reasonable.
The contrarian case I'd actually worry about isn't Amazon — it's pet adoption normalization. US pet ownership surged during COVID and the cohort is aging; vet/food spend per household may have peaked. If category growth slows from mid-single to low-single digits, Chewy's 6% topline drops to 2-3% and the multiple compresses. The decelerating quarterly trend the Revenue Confidence flag picked up is consistent with this. Second worry: the insider activity is genuinely ugly — an 83,306 share S-Sale on 5/4/2026 alongside multiple F-InKind tax withholdings, with zero offsetting open-market buys in the visible window. That's not "unusual heavy selling" in a panic sense, but it's confirmation that insiders see fair-to-full value here, not upside. Third worry: current ratio of 0.88 means Chewy runs on negative working capital (supplier float), which is fine until growth stalls and the float reverses — a known failure mode for scaled e-comm.
I dissent mildly with the synthesis's "uncomfortable middle ground" framing — I think the setup is cleaner than that. At $19.31 and ~$8B market cap on $562M FCF growing 20%+ (FCF CAGR 28.1% is real, even if it decelerates to 10-15%), you're paying 14x FCF for a #1/#2 category specialist with proven margin expansion, structural Autoship recurring revenue (~80% of sales), and option value on Chewy Health/vet clinics. The narrative engine's DCF anchor of ~$17.70 with a 9% story premium feels about right on point estimate but understates the asymmetry — downside to $15 if growth stalls (12x FCF, distressed-mature multiple), upside to $28-30 if vet clinics scale and FCF compounds at 15% for three years (18x on $750M FCF). That's roughly 2:1 reward/risk at current price. Not a screaming buy, but the bear thesis requires both Amazon to finally win after losing for a decade *and* category normalization — possible but not the base case. Insider selling and decelerating quarterly trends keep me from sizing aggressively.
GPT Critique
Upon analyzing Chewy's recent financial data, several key trends emerge. Revenue growth has been steady, with a CAGR of 6.3% over the recent years, reflecting a consistent upward trajectory, albeit with some deceleration noted in recent quarters. The company's gross margin has expanded from 26.6% in FY22 to 29.8% in FY26, indicating improved operational efficiency despite competitive pressures, particularly from Amazon. However, net income has been volatile, with significant fluctuations such as the drop from $299.1M in Q3 2024 to $39.2M in Q1 2026, suggesting potential one-time benefits or cost management challenges. Chewy's free cash flow margin of approximately 4.5% is robust, which is significant for a company in a competitive e-commerce space. The absence of total debt and a healthy cash position of $860.1M underscore a solid balance sheet, which can support further strategic investments or buffer against economic downturns.
I find myself in partial agreement with Claude Opus's analysis, particularly regarding the valuation metrics. Opus argues that the focus should be on the EV/FCF ratio of approximately 13-14x rather than the PE ratio, which is distorted due to accounting dynamics. I concur that the EV/FCF ratio provides a clearer picture of Chewy's valuation, given its strong cash flow generation. However, I diverge on the perceived threat from Amazon. Opus downplays Amazon's competitive impact, but I believe that Amazon's ongoing presence is a significant risk factor, especially as Chewy's revenue growth appears to be slowing, as indicated by the Revenue Confidence flag.
Opus also highlights insider selling as a concern, which I agree is noteworthy. The significant S-Sale of 83,306 shares without any corresponding purchases is indicative of potential insider skepticism about future growth prospects. Additionally, Opus mentions the potential normalization of pet adoption rates post-COVID as a risk, which aligns with the slowing revenue trend and should not be underestimated. This could indeed pressure Chewy's growth trajectory and necessitate a reassessment of its market positioning and product offerings.
A careful skeptic might argue that both Opus and my assessments could undervalue Chewy's potential for innovation and expansion into adjacent markets like veterinary services and pet healthcare. While these are currently aspirational, successful execution could significantly alter the growth narrative. Additionally, they might point out that the market's valuation already reflects these risks, offering a potential buying opportunity if Chewy can sustain its growth and margin improvements.